ArticleFuture oncology (London, England)2025

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.

John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.